Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB059872 in advanced malignancies
NL-OMON48925Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of incb059872 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis (MF) and 4 more (9 arms), sponsored by Incyte. Primary endpoints: Safety and tolerability of INCB059872 monotherapy and Safety and tolerability of INCB059872 combination therapy. Started Jun 2019; status: active, not recruiting.
02
Drugs
incb059872
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)small cell lung cancer (SCLC)Ewing sarcoma
Beyond the preview
Go deeper on NL-OMON48925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48925.